Zenshine Pharmaceuticals focuses on the discovery and development of small molecule therapeutics, particularly targeting purinergic signaling in immune cells and intracellular signal transduction pathways. Their innovative approach aims to modulate the tumor microenvironment to enhance immune responses against cancer. The company’s pipeline includes several promising candidates, such as ZX-7101A, which is designed to treat influenza by inhibiting viral proteins, and ZX-4081, a selective PI3Kγ inhibitor that shows potential in overcoming resistance to existing cancer therapies. Zenshine's commitment to developing best-in-class and first-in-class therapies is evident in their strategic focus on oncology, anti-infection, and inflammatory diseases.

The company employs a science-centric discovery platform that emphasizes the importance of small molecules in targeted therapies. These small molecules offer advantages over biologic therapeutics, including lower costs, oral bioavailability, and the ability to access intracellular targets. Zenshine's research and development efforts are directed towards creating novel therapies that can effectively address unmet medical needs, particularly in cancer and infectious diseases. By leveraging their expertise in small molecule R&D, Zenshine aims to deliver innovative treatments that improve patient outcomes and address the complexities of disease mechanisms.

United States

Zenshine is a clinical stage biopharmaceutical company, focused on small molecule therapeutics in the areas of cancer, viral infection and inflammation. Our mission is to apply the best science to serve patients.

Zenshine leverages the team’s extensive expertise and experience in developing proprietary chemical entities with well-defined differentiation to  benefit the patients. By targeting key biological pathways to disrupt virus replication, directly block tumor growth and enhance anti-tumor immune responses, Zenshine commits to providing bench-side to bed-side solutions and delivering the best-in-class or first-in-class therapeutics.

Zenshine Pharmaceuticals

Company Details